Correction: Strong Trauma/LOQTEQ® sales growth in the first nine months of 2013
(Thomson Reuters ONE) -
aap Implantate AG /
Correction: Strong Trauma/LOQTEQ® sales growth in the first nine months of 2013
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) increased its total sales by 3 % to EUR 28.4
million (previous year: EUR 27.5 million) in the first nine months of 2013.
EBITDA at EUR 5.3 million (previous year: EUR 4.8 million), was up by 11 % year
on year.
+--------------+---------+---------+--------+
| In ? million | 9m/2013 | 9m/2012 | Change |
+--------------+---------+---------+--------+
| Sales | 28.4 | 27.5 | 3% |
+--------------+---------+---------+--------+
| EBITDA | 5.3 | 4.8 | 11% |
+--------------+---------+---------+--------+
| Cash-EBITDA | 3.8 | 2.5 | 53% |
+--------------+---------+---------+--------+
| Cash-EBT | 2.4 | 0.8 | >100% |
+--------------+---------+---------+--------+
+--------------+---------+---------+--------+
| In ? million | Q3/2013 | Q3/2012 | Change |
+--------------+---------+---------+--------+
| Sales | 8.8 | 8.6 | 2% |
+--------------+---------+---------+--------+
| EBITDA | 1.1 | 1.2 | -12% |
+--------------+---------+---------+--------+
| Cash-EBITDA | 0.7 | 0.4 | 68% |
+--------------+---------+---------+--------+
| Cash-EBT | 0.2 | -0.2 | >100% |
+--------------+---------+---------+--------+
In the first nine months and the third quarter, we achieved the following
highlights:
* Trauma sales (incl. LOQTEQ®) in the third quarter increased 50% to ?2.2
million (previous year: ?1.5 million) and increased 63% to ?6.5 million in
the first nine months (previous year: ?4.0 million)
* LOQTEQ® sales increased by ?0.5 million to ?1.1 million (+83%) in the third
quarter of 2013 (previous year: ?0.6 million) and by 182% to ?3.1 million in
the first nine months (previous year: ?1.1 million)
* Turnover rate of Working capital (based on last four quarter sales) improved
from 2.25 (30.9.2012) to 2.31 (+3%)
* Net debt (interest bearing) reduction from ?4.3 million (31.12.2012) to ?3.0
million
* Intangible assets percentage (as of the balance sheet total) reduction from
57% (31.12.2012) to 52%
Given the importance of the LOQTEQ® product family and our focus on the Trauma
market, we would like to highlight the following activities:
* Signing a new distribution agreement for LOQTEQ® with an Saudi Arabian
distributor, first supply will be shipped in the fourth quarter 2013
* Delivering the first supply of LOQTEQ® products to our distributor in
Bulgaria
* Receiving CE-approval for four of the six new LOQTEQ® plating systems (phase
2), two of them already received FDA-approval.
* Continuing the LOQTEQ® post marketing study, with initial reports
demonstrating very promising fracture repair qualities and ease of use,
including no reported cases of cold welding
Outlook 2013
For the fourth quarter of 2013, the management board forecasts sales in the
range of ?10.5 million to ?11.6 million and an EBITDA of ?1.3 million to ?1.7
million. Sales and profitability will be mainly driven by sales of trauma
products, especially LOQTEQ®, and as previously announced, bone cement and
cementing devices.
The Outlook for the fourth quarter 2013 supports the reconfirmation of the full
year forecast of sales growth of 10% to approx. ?40 million and an EBITDA growth
of approx. 15% to ?7 million.
The evaluation process of the strategic options for EMCM is ongoing.
aap Implantate AG's full Q3 2013 report is available to download at www.aap.de.
______________________________________________________
About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that are
used in orthopedic procedures. The Company's products, which include a full line
of plating systems, cannulated screws and bone cement products, are primarily
used in the orthopedic specialty areas of trauma and spine repair. The Company's
products are sold through its direct sales force, distribution partners and
license agreements with OEM partners. aap's stock is listed in the Prime
Standard segment of the Frankfurt Stock Exchange. For more information, please
visit www.aap.de, or download the Company's investor relations app from the
Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin,
Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich(at)aap.de
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
[HUG#1742182]
Unternehmensinformation / Kurzprofil:
Datum: 11.11.2013 - 15:09 Uhr
Sprache: Deutsch
News-ID 314964
Anzahl Zeichen: 7071
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Correction: Strong Trauma/LOQTEQ® sales growth in the first nine months of 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
